Allergy

Dupilumab fails to improve peanut allergy desensitization in children

February 11, 2025

While dupilumab monotherapy can reduce IgE levels, it doesn't significantly improve desensitization to peanut exposure in children with peanut allergy.

Study design: This multicenter, open-label, phase 2 study evaluated the efficacy and safety of dupilumab in children aged 6 to 17 years with confirmed peanut allergy. The study involved a 24-week treatment period where participants received SC dupilumab every 2 weeks. The primary endpoint was the proportion of participants who passed a double-blind placebo-controlled food challenge (DBPCFC) with ≥444 mg of peanut protein at week 24.

Results: Out of 24 participants, only 8.3% achieved the primary endpoint by passing the DBPCFC at week 24. Dupilumab treatment resulted in a median reduction of total and peanut-specific IgE levels by −54% and −49%, respectively. However, there was no significant change in peanut-specific IgG4 levels. Treatment-emergent adverse events were reported in 62.5% of participants, all of mild or moderate intensity. At the week 24 food challenge, 8 participants (33.3%) experienced a grade 2 allergic reaction (no grade 3 or higher); 10 (41.7%) required adrenaline as a rescue medication.

Source:

Sindher SB, et al. (2024, December 14). Allergy. Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study. https://pubmed.ncbi.nlm.nih.gov/39673452/